Pharmacogenomics in Drug Discovery and Development

Edited by

Qing Yan

PharmTao, Santa Clara, CA, USA
Contents

Chapter 1  The Integration of Personalized and Systems Medicine: 
Bioinformatics Support for Pharmacogenomics 
and Drug Discovery ........................................ 1
Qing Yan

Chapter 2  Applications of Microarrays and Biochips in Pharmacogenomics ........................................ 21
Gary Hardiman

Chapter 3  Confounding in Genetic Association Studies 
and Its Solutions ............................................... 31
Donglei Hu and Elad Ziv

Chapter 4  Pharmacogenetics of Membrane Transporters: A Review 
of Current Approaches ........................................ 41
Tristan M. Sissung, Erin R. Gardner, Rui Gao, and William D. Figg

Chapter 5  Pharmacogenomics of Drug-Metabolizing Enzymes and Drug Transporters in Chemotherapy ....... 63
Tessa M. Bosch

Chapter 6  Pharmacogenomics of G Protein-Coupled Receptor Signaling: Insights from Health and Disease ............. 77
Miles D. Thompson, David E. C. Cole, and Pedro A. Jose

Chapter 7  G Protein-Coupled Receptors Disrupted in Human Genetic Disease ........................................... 109
Miles D. Thompson, Maire E. Percy, W. McIntyre Burnham, and David E. C. Cole
Chapter 8  G Protein-Coupled Receptor Pharmacogenetics ............... 139
Miles D. Thompson, Katherine A. Siminoivitch, and David E. C. Cole

Chapter 9  Epigenetic Alterations of the Dopaminergic System in Major Psychiatric Disorders .............................................. 187
Hamid Mostafavi Abdolmaleky, Cassandra L. Smith, Jin-Rong Zhou, and Sam Thiagalingam

Chapter 10  Pharmacogenomics in Alzheimer’s Disease ............... 213
Ramón Cacabelos

Chapter 11  Pharmacogenetics of Asthma ................................. 359
Gregory A. Hawkins and Stephen P. Peters

Chapter 12  From SNPs to Functional Studies in Cardiovascular Pharmacogenomics ......................................................... 379
Sharon Cresci

Chapter 13  Pharmacogenomics in Gastrointestinal Disorders ....... 395
Michael Camilleri and Yuri A. Saito

Chapter 14  Pharmacogenomics in Rheumatoid Arthritis .......... 413
Prabha Ranganathan

Chapter 15  Cancer Pharmacogenetics ................................. 437
Sharon Marsh

Chapter 16  Pharmacogenomics in the Preclinical Development of Vaccines: Evaluation of Efficacy and Systemic Toxicity in the Mouse Using Array Technology ................................. 447
Karin J. Regnström

Chapter 17  Pharmacogenomics in the Evaluation of Efficacy and Adverse Events During Clinical Development of Vaccines ......................... 469
Lennart J. Nilsson and Karin J. Regnström

Index .............................................................. 481